BAKER BROS ADVISORS LLC Insider Trading $NLTX Neoleukin Therapeutics, Inc.
Get free email notifications about insider trading for BAKER BROS ADVISORS LLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of BAKER BROS ADVISORS LLC. BAKER BROS ADVISORS LLC is 10% Owner in BIOCRYST PHARMACEUTICALS INC ($BCRX) and Director in INCYTE CORP ($INCY) and Director in ALEXION PHARMACEUTICALS INC ($ALXN) and 10% Owner in IDERA PHARMACEUTICALS, INC. ($IDRA) and Director in IDERA PHARMACEUTICALS, INC. ($IDRA) and in XOMA Corp ($XOMA) and Director in ACADIA PHARMACEUTICALS INC ($ACAD) and Director in SEATTLE GENETICS INC /WA ($SGEN) and Director in GENOMIC HEALTH INC ($GHDX) and 10% Owner in BELLICUM PHARMACEUTICALS, INC ($BLCM) and 10% Owner in AQUINOX PHARMACEUTICALS, INC ($AQXP) and Director in AQUINOX PHARMACEUTICALS, INC ($AQXP) and Director in Zymeworks Inc. ($ZYME) and Director in Kodiak Sciences Inc. ($KOD) and 10% Owner in Invitae Corp ($NVTA) and Director in IGM Biosciences, Inc. ($IGMS) and 10% Owner in Atreca, Inc. ($BCEL) and in Mirati Therapeutics, Inc. ($MYG) and 10% Owner in Mirati Therapeutics, Inc. ($MYG) and Director in Talis Biomedical Corp ($TLIS) and Director in Aeglea BioTherapeutics, Inc. ($AGLE) and in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and in Intellia Therapeutics, Inc. ($NTLA) and Director in BeiGene, Ltd. ($BGNE) and Director in Prelude Therapeutics Inc ($PRLD) and Director in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and in HOOKIPA Pharma Inc. ($HOOK).
BAKER BROS ADVISORS LLC in Neoleukin Therapeutics, Inc.
Trading Symbol: NLTXIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of BAKER BROS ADVISORS LLC: Director, 10% Owner
Holdings: 320,049 shares
Current Value: $6,020,122
Latest Transaction: May 13 2021
$NLTX Market Capitalization: $451.60M
$NLTX Previous Close: $18.81
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of BAKER BROS ADVISORS LLC in Neoleukin Therapeutics, Inc.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACAD, AGLE, ALXN, BCEL, BGNE, BLCM, BCRX, GHDX, HOOK, IDRA, IGMS, INCY, NTLA, NVTA, KNSA, KOD, MYG, NLTX, PRLD, RYTM, SGEN, TLIS, XOMA, ZYME
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 13 2021 | NLTX | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 11.40 | 25,000 | 285,000 | 25,000 | |
Dec 23 2020 | NLTX | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | P | 0.00 | 518,555 | 0 | 10,283,888 | |
Dec 23 2020 | NLTX | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | P | 0.00 | 38,974 | 0 | 1,199,122 | |
Dec 23 2020 | NLTX | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 15.25 | 394,360 | 6,013,990 | 3,501,691 | 3.1 M to 3.5 M (+12.69 %) |
Dec 23 2020 | NLTX | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 15.25 | 29,640 | 452,010 | 320,049 | 290.4 K to 320 K (+10.21 %) |
May 07 2020 | NLTX | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 12.84 | 25,000 | 321,000 | 25,000 | |
Dec 20 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 0.00 | 9,765,333 | 0 | 9,765,333 | |
Dec 20 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 0.00 | 1,160,148 | 0 | 1,161,048 | |
Dec 20 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Sell | D | 0.00 | 9,765,333 | 0 | 3,107,331 | 12.9 M to 3.1 M (-75.86 %) |
Dec 20 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Sell | D | 0.00 | 1,160,148 | 0 | 290,409 | 1.5 M to 290.4 K (-79.98 %) |
Dec 20 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 8.40 | 2,767,505 | 23,247,042 | 12,872,664 | 10.1 M to 12.9 M (+27.39 %) |
Dec 20 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 8.40 | 250,037 | 2,100,311 | 1,450,557 | 1.2 M to 1.5 M (+20.83 %) |
Oct 15 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 2.82 | 22,000 | 62,040 | 22,000 | |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 3.15 | 50,436 | 159,020 | 10,105,159 | 10.1 M to 10.1 M (+0.50 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 3.15 | 4,564 | 14,390 | 1,200,520 | 1.2 M to 1.2 M (+0.38 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 3.02 | 209,382 | 633,255 | 10,054,723 | 9.8 M to 10.1 M (+2.13 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 3.02 | 18,943 | 57,291 | 1,195,956 | 1.2 M to 1.2 M (+1.61 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 2.96 | 5,869 | 17,358 | 9,845,341 | 9.8 M to 9.8 M (+0.06 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 2.96 | 531 | 1,570 | 1,177,013 | 1.2 M to 1.2 M (+0.05 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 2.85 | 65,568 | 186,666 | 9,839,472 | 9.8 M to 9.8 M (+0.67 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 2.85 | 5,932 | 16,888 | 1,176,482 | 1.2 M to 1.2 M (+0.51 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 2.83 | 9,445 | 26,756 | 9,773,904 | 9.8 M to 9.8 M (+0.10 %) |
Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 2.83 | 855 | 2,422 | 1,170,550 | 1.2 M to 1.2 M (+0.07 %) |
May 09 2018 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 13.10 | 30,000 | 393,000 | 30,000 | |
May 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 13.74 | 36,000 | 494,640 | 36,000 | |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 17.76 | 32,051 | 569,226 | 9,764,459 | 9.7 M to 9.8 M (+0.33 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 17.76 | 3,389 | 60,189 | 1,169,695 | 1.2 M to 1.2 M (+0.29 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 17.60 | 235,169 | 4,138,880 | 9,732,408 | 9.5 M to 9.7 M (+2.48 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 17.60 | 24,871 | 437,720 | 1,166,306 | 1.1 M to 1.2 M (+2.18 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 16.31 | 35,360 | 576,555 | 9,497,239 | 9.5 M to 9.5 M (+0.37 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 16.31 | 3,739 | 60,966 | 1,141,435 | 1.1 M to 1.1 M (+0.33 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 15.62 | 5,006 | 78,207 | 9,461,879 | 9.5 M to 9.5 M (+0.05 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 15.62 | 529 | 8,264 | 1,137,696 | 1.1 M to 1.1 M (+0.05 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 15.13 | 15,148 | 229,189 | 9,456,873 | 9.4 M to 9.5 M (+0.16 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 15.13 | 1,602 | 24,238 | 1,137,167 | 1.1 M to 1.1 M (+0.14 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 16.20 | 9,143 | 148,089 | 9,441,725 | 9.4 M to 9.4 M (+0.10 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 16.20 | 967 | 15,662 | 1,135,565 | 1.1 M to 1.1 M (+0.09 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 15.35 | 8,671 | 133,078 | 9,432,582 | 9.4 M to 9.4 M (+0.09 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 15.35 | 917 | 14,074 | 1,134,598 | 1.1 M to 1.1 M (+0.08 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 16.85 | 2,442 | 41,156 | 9,423,911 | 9.4 M to 9.4 M (+0.03 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 16.85 | 258 | 4,348 | 1,133,681 | 1.1 M to 1.1 M (+0.02 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 15.32 | 11,305 | 173,204 | 9,421,469 | 9.4 M to 9.4 M (+0.12 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 15.32 | 1,195 | 18,309 | 1,133,423 | 1.1 M to 1.1 M (+0.11 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 16.74 | 5,697 | 95,365 | 9,410,164 | 9.4 M to 9.4 M (+0.06 %) |
Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 16.74 | 603 | 10,094 | 1,132,228 | 1.1 M to 1.1 M (+0.05 %) |
Sep 21 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 13.15 | 12,550 | 165,029 | 1,131,625 | 1.1 M to 1.1 M (+1.12 %) |
Sep 21 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 12.25 | 2,476,348 | 30,335,263 | 9,404,467 | 6.9 M to 9.4 M (+35.74 %) |
Sep 21 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 12.25 | 294,707 | 3,610,161 | 1,119,075 | 824.4 K to 1.1 M (+35.75 %) |
Mar 16 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.16 | 128,975 | 1,051,920 | 6,928,119 | 6.8 M to 6.9 M (+1.90 %) |
Mar 16 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.16 | 14,046 | 114,559 | 824,368 | 810.3 K to 824.4 K (+1.73 %) |
Mar 16 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 7.91 | 185,413 | 1,466,320 | 6,799,144 | 6.6 M to 6.8 M (+2.80 %) |
Mar 16 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 7.91 | 20,192 | 159,686 | 810,322 | 790.1 K to 810.3 K (+2.56 %) |
Mar 16 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 7.70 | 11,840 | 91,160 | 6,613,731 | 6.6 M to 6.6 M (+0.18 %) |
Mar 16 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 7.70 | 1,289 | 9,924 | 790,130 | 788.8 K to 790.1 K (+0.16 %) |
Mar 16 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.03 | 68,132 | 546,807 | 6,601,891 | 6.5 M to 6.6 M (+1.04 %) |
Mar 16 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.03 | 7,420 | 59,551 | 788,841 | 781.4 K to 788.8 K (+0.95 %) |
Mar 16 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 7.88 | 30,986 | 244,126 | 6,533,759 | 6.5 M to 6.5 M (+0.48 %) |
Mar 16 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 7.88 | 3,374 | 26,582 | 781,421 | 778 K to 781.4 K (+0.43 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 11.00 | 3,581 | 39,377 | 6,502,773 | 6.5 M to 6.5 M (+0.06 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 11.00 | 395 | 4,343 | 778,047 | 777.7 K to 778 K (+0.05 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.80 | 66,345 | 716,745 | 6,499,192 | 6.4 M to 6.5 M (+1.03 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.80 | 7,318 | 79,059 | 777,652 | 770.3 K to 777.7 K (+0.95 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 11.20 | 2,522 | 28,257 | 6,432,847 | 6.4 M to 6.4 M (+0.04 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 11.20 | 278 | 3,115 | 770,334 | 770.1 K to 770.3 K (+0.04 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.98 | 4,503 | 49,423 | 6,430,325 | 6.4 M to 6.4 M (+0.07 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.98 | 497 | 5,455 | 770,056 | 769.6 K to 770.1 K (+0.06 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 11.23 | 2,833 | 31,822 | 6,425,822 | 6.4 M to 6.4 M (+0.04 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 11.23 | 312 | 3,505 | 769,559 | 769.2 K to 769.6 K (+0.04 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.69 | 25,650 | 274,219 | 6,422,989 | 6.4 M to 6.4 M (+0.40 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.69 | 2,810 | 30,041 | 769,247 | 766.4 K to 769.2 K (+0.37 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.60 | 156 | 1,654 | 6,397,339 | 6.4 M to 6.4 M (0.00 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.60 | 17 | 180 | 766,437 | 766.4 K to 766.4 K (0.00 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.69 | 4,021 | 42,999 | 6,397,183 | 6.4 M to 6.4 M (+0.06 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.69 | 440 | 4,705 | 766,420 | 766 K to 766.4 K (+0.06 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.78 | 17,221 | 185,666 | 6,393,162 | 6.4 M to 6.4 M (+0.27 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.78 | 1,887 | 20,345 | 765,980 | 764.1 K to 766 K (+0.25 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.90 | 1,734 | 15,433 | 6,375,941 | 6.4 M to 6.4 M (+0.03 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.90 | 190 | 1,691 | 764,093 | 763.9 K to 764.1 K (+0.02 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.96 | 27,996 | 250,766 | 6,374,207 | 6.3 M to 6.4 M (+0.44 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.96 | 3,067 | 27,472 | 763,903 | 760.8 K to 763.9 K (+0.40 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.96 | 13,789 | 123,493 | 6,346,211 | 6.3 M to 6.3 M (+0.22 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.96 | 1,511 | 13,532 | 760,836 | 759.3 K to 760.8 K (+0.20 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 9.89 | 57,453 | 567,934 | 6,332,422 | 6.3 M to 6.3 M (+0.92 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 9.89 | 6,294 | 62,217 | 759,325 | 753 K to 759.3 K (+0.84 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 9.15 | 14,313 | 131,017 | 6,274,969 | 6.3 M to 6.3 M (+0.23 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 9.15 | 1,568 | 14,353 | 753,031 | 751.5 K to 753 K (+0.21 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 9.21 | 10,123 | 93,282 | 6,260,656 | 6.3 M to 6.3 M (+0.16 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 9.21 | 1,109 | 10,219 | 751,463 | 750.4 K to 751.5 K (+0.15 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 9.08 | 45,903 | 416,602 | 6,250,533 | 6.2 M to 6.3 M (+0.74 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 9.08 | 5,029 | 45,642 | 750,354 | 745.3 K to 750.4 K (+0.67 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.56 | 47,193 | 403,930 | 6,204,630 | 6.2 M to 6.2 M (+0.77 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.56 | 5,196 | 44,473 | 745,325 | 740.1 K to 745.3 K (+0.70 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.95 | 4,949 | 44,308 | 6,157,437 | 6.2 M to 6.2 M (+0.08 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.95 | 545 | 4,879 | 740,129 | 739.6 K to 740.1 K (+0.07 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.82 | 3,279 | 28,937 | 6,152,488 | 6.1 M to 6.2 M (+0.05 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.82 | 361 | 3,186 | 739,584 | 739.2 K to 739.6 K (+0.05 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.10 | 20,851 | 168,891 | 6,149,209 | 6.1 M to 6.1 M (+0.34 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.10 | 2,296 | 18,597 | 739,223 | 736.9 K to 739.2 K (+0.31 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.08 | 2,998 | 24,213 | 6,128,358 | 6.1 M to 6.1 M (+0.05 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.08 | 330 | 2,665 | 736,927 | 736.6 K to 736.9 K (+0.04 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 7.91 | 12,706 | 100,517 | 6,125,360 | 6.1 M to 6.1 M (+0.21 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 7.91 | 1,399 | 11,067 | 736,597 | 735.2 K to 736.6 K (+0.19 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.17 | 90,550 | 739,947 | 6,112,654 | 6 M to 6.1 M (+1.50 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.17 | 9,970 | 81,472 | 735,198 | 725.2 K to 735.2 K (+1.37 %) |
Sep 11 2015 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 15.50 | 2,213,469 | 34,308,770 | 6,022,104 | 3.8 M to 6 M (+58.12 %) |
Sep 11 2015 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 15.50 | 266,563 | 4,131,727 | 725,228 | 458.7 K to 725.2 K (+58.12 %) |
Page: 1